Triple Test

The triple test is the standard diagnostic framework for evaluating a breast lump. The principle is that all three components must be concordant — if any one is discordant (e.g. benign on two but suspicious on one), the lesion needs excision biopsy regardless. The three components:

1. Clinical assessment — history and examination. Age matters enormously as a prior probability: a lump in a 20-year-old is overwhelmingly likely to be a fibroadenoma, whereas a new lump in a 60-year-old is cancer until proven otherwise. You're assessing the lump's characteristics (hard/soft, mobile/fixed, regular/irregular), skin changes (tethering, peau d'orange, dimpling), nipple changes (retraction, discharge — especially bloody/unilateral), and axillary lymphadenopathy. Each component gets scored 1 (benign), 2 (suspicious/uncertain), or 3 (malignant) in some systems, though in practice it's often more gestalt.
2. Imaging — mammography and/or ultrasound. Under 35, ultrasound is first-line because the dense breast parenchyma limits mammographic sensitivity. Over 35, both are typically used. Reported using BI-RADS (1–5 scale). Key features suggesting malignancy: spiculated mass, irregular margins, architectural distortion, pleomorphic microcalcifications (especially linear/branching — reflecting calcification within DCIS in ducts). Benign features: well-circumscribed, oval, parallel orientation, macrocalfications. Ultrasound additionally distinguishes solid from cystic — a simple cyst (anechoic, posterior acoustic enhancement, thin wall) can essentially be diagnosed on ultrasound alone and doesn't need biopsy unless symptomatic.
3. Tissue sampling — core biopsy is now the standard, having largely replaced fine needle aspiration (FNA) for solid lesions. Core biopsy is preferred because it provides architectural information (can distinguish DCIS from invasive disease, can assess grade, can do IHC for ER/PR/HER2/Ki-67), whereas FNA only gives cytology. FNA is still useful for cyst aspiration and for sampling axillary nodes. Core biopsy is reported as B1–B5 (B1 normal/inadequate, B2 benign, B3 uncertain malignant potential, B4 suspicious, B5 malignant).

Why it works: Each component alone has a false-negative rate, but when all three agree, the combined accuracy for both benign and malignant diagnoses exceeds 99%. The power is in concordance. A classic scenario where it saves you: a clinically benign-feeling lump in a young woman, benign on ultrasound, but core biopsy shows atypia — that discordance mandates further workup. Conversely, if all three say fibroadenoma, you can safely observe.